We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Affimed NV (AFMD) EUR0.1

Sell:$4.07 Buy:$4.12 Change: $0.04 (0.98%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.07
Buy:$4.12
Change: $0.04 (0.98%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.07
Buy:$4.12
Change: $0.04 (0.98%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Contact details

Address:
Gottlieb-Daimler-Strasse 2
MANNHEIM
68165
Germany
Telephone:
+49 (621) 560030
Website:
https://www.affimed.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AFMD
ISIN:
NL0015001ZQ0
Market cap:
$60.61 million
Shares in issue:
15.68 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Netherlands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Hecht
    Independent Chairman of the Supervisory Board
  • Shawn Leland
    Chief Executive Officer, Member of the Management Board
  • Harry Welten
    Consulting Chief Financial Officer, Member of the Management Board
  • Wolfgang Fischer
    Chief Operating Officer, Member of the Management Board
  • Andreas Harstrick
    Chief Medical Officer, Member of the Management Board
  • Denise Mueller
    Chief Business Officer and Co-President Affimed Inc, Member of the Management Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.